ClinicalTrials.gg
RecruitingNCT07093346PEC-MASLDUpdated Jul 29, 2026

The Impact of Pectin Supplementation on Systematic Inflammation Pathway, Gut Microbiome, and Metabolic Health in Patients With Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD)

An interventional study of Pectin and Cocoa Powder in Nonalcoholic Fatty Liver Disease, Nonalcoholic Fatty Liver Disease (NAFLD) and MASLD - Metabolic Dysfunction-Associated Steatotic Liver Disease, sponsored by University of Nottingham. Recruiting at 3 sites in United Kingdom. Open to participants aged 18 Years and older, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-07-29.

Sponsored by University of Nottingham · Not applicable, Interventional, and Basic science

How we know

From the registry’s dates

  • Started Jun 2025; still recruiting 1 year 5 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
45
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 122 studies in Non-alcoholic Fatty Liver Disease with a site in United Kingdom — 17 open to participants now, 27 under way, 9 of them phase 3. Non-alcoholic Fatty Liver Disease · United Kingdom.

Planned enrollment
69th of 101
45 · median 104
Started
2025
with 5 others
No phase
30 of 122
3 open now
Primary completion
2027-03
later than 9 of 26 live
Registered
120th of 122
by date
Lead sponsor
5 of 122
University of Nottingham

Among the 122 studies in Non-alcoholic Fatty Liver Disease with a site in United Kingdom, this one is the 69th largest by planned enrollment of the 101 interventional ones that give a count, is one of 6 that started in 2025, is one of 30 with no phase, reaches primary completion later than 9 of the 26 other live ones, and was the 120th registered.

Non-alcoholic Fatty Liver Disease

1,618 studies on the registry are indexed under Non-alcoholic Fatty Liver Disease; 322 are open to participants now.

Browse Non-alcoholic Fatty Liver Disease studies →

Open to participants now

17 of the 122 studies in Non-alcoholic Fatty Liver Disease with a site in United Kingdom are open now. Recruiting first, the newest first:

11 more — sign in →

All 17 open studies →

A study can be open while its sites in United Kingdom have not opened yet or have stopped. Only those recruiting at a site in United Kingdom →

Who these studies take

Of the 219 Non-alcoholic Fatty Liver Disease studies recruiting now, 66 (30%) set no upper age limit and 124 (57%) stop at 75 or younger; 27 take children under 18; 55 take healthy volunteers.

This study: 18 Years and older · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 122 studies in Non-alcoholic Fatty Liver Disease with a site in United Kingdom, or all of them as a file.
02

Study summary

The goal of this clinical trial is to learn if daily supplementation with Low-methoxy (LM) pectin (polysaccharides extracted from citrus peels), which are commonly found in the UK diet (not pharmacological agents), can reduce systemic inflammation and improve gut microbiota composition in adults recently diagnosed with Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD). The main question it aims to answer is:

-How does dietary Low-methoxy (LM) pectin supplementation affect systematic inflammation pathways such as those mediated by gut microbiota composition and what are the impacts on general metabolic indicators in individuals with MASLD?

Researchers will compare a group taking 15g of LM-pectin with 10g of cocoa powder to a placebo group receiving 10g of placebo with 10g of cocoa powder to see if LM-pectin has measurable effects on inflammation and gut microbiota.

Participants will:

  • Take a daily supplement for 6 weeks: either 15g of LM-pectin with 10g of cocoa powder (intervention), or 10g of placebo with 10g of cocoa powder (control)
  • Provide stool and fasting blood samples before and after the intervention
  • Undergo anthropometric measurements (weight, height, waist/hip ratio, and blood pressure)
  • Complete a case report form (CRF) including demographics and health/medical history
  • Undergo a FibroScan™ to assess liver health
  • (Optional) Participate in MRI scans to evaluate gut permeability
Read the detailed description

Primary Objective:

This research aims to study the effects of daily ingestion of LM pectin on inflammation pathways by measuring the blood inflammatory markers associated with physiological processes (TNFα, IL-6, IL-10, IFNᵞ, C - reactive protein, Zonulin (Haptoglobulin), IL-1β).

Secondary Objectives:

  1. Assessment of changes in anthropometric measures.
  2. Assessment of changes in general metabolic indicators, such as fasting blood glucose and other blood-based markers relevant to MASLD (e.g., CK18-M30, CK18-M65, PROC3, Enhanced Liver Fibrosis (ELF), NIS2+™, YKL-40, microRNA miR-34a-5p, liver-associated enzymes such as Alanine Aminotransferase (ALT), Aspartate Aminotransferase (AST), gamma-glutamyl transferase (GGT), Alkaline Phosphatase (ALP)), bilirubin levels, lipid profiles, and platelet counts.
  3. Exploration of changes in gut microbiome composition.
  4. Exploration of modifications in non-invasive physiological assessments linked to liver characteristics, such as fat content and stiffness through controlled attenuation parameter (CAP) and transient elastography.
  5. Observation of alteration in fat in liver and other surrounding abdominal organs through Dixon MRI sequence in patients who will agree to have 2 MRI scans.
  6. Validation of MRI measures (T2*) as a tool to measure gut permeability among MASLD patients and investigation of changes in gut permeability in participants undergoing two MRI scans.
  7. Investigation the presence of gene variants such as MUC2, encoding Mucin protein, that are associated with gut permeability.
03

Conditions studied

  • Nonalcoholic Fatty Liver Disease
  • Nonalcoholic Fatty Liver Disease (NAFLD)
  • MASLD - Metabolic Dysfunction-Associated Steatotic Liver Disease
  • MASLD
  • NAFLD
  • Metabolic Dysfunction-Associated Steatotic Liver Disease
  • NAFLD (Nonalcoholic Fatty Liver Disease)
  • NAFLD (Non-alcoholic Fatty Liver Disease)
  • NAFLD - Non-Alcoholic Fatty Liver Disease
  • NAFLD - Nonalcoholic Fatty Liver Disease

Keywords

  • LM pectin
  • pectin
  • MASLD
  • NAFLD
  • Nonalcoholic Fatty Liver Disease
  • Systemic Inflammatory Response
  • Dietary Fiber
  • Dietary Fibre
  • Diet
  • gut microbiota
  • Metabolic Dysfunction-Associated Steatotic Liver Disease
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
Yes

Eligibility criteria

Inclusion Criteria:

Inclusion criteria for the main study:

  • Patients with clinical diagnosis of MASLD (formerly termed non-alcoholic fatty liver disease (NAFLD)), having assessment suggesting that liver fat > 5% (e.g. histological evidence or/ and Transient Elastography using Controlled Attenuation Parameter (CAP)- FibroScan™ in the past month and/or liver imaging (such as ultrasound, computerized tomography (CT) or magnetic resonance imaging (MRI)).
  • Participants willing and able to give for participation in the study.
  • Participants aged ≥18 years who have a (BMI) between 18.5 and 39.9 kg/m2 and stable weight (weight gain or loss ≤ 3kg) for the past 3 months.
  • For diabetic participants: controlled blood glucose levels (HbA1c) \<7.0% (\<53 mmol/mol) [1].
  • Able to undergo CAP-FibroScan™.

Inclusion criteria for healthy participants who will have MRI scans:

  • Participants willing and able to give informed consent for participation in the study.
  • Participants aged ≥18 years.
  • participants with CAP\<250 kpa\<8kP by a FibroScan™ within the past 6 months.

Exclusion Criteria:

Exclusion criteria for the main study:

  • Have allergy toward soya, milk or chocolate.
  • Have allergy toward pectin.
  • Participants on vegan diet.
  • Have eating disorders or difficulties or gastrointestinal conditions e.g. malabsorptive conditions such as coeliac, Irritable Bowel Syndrome (IBS) or Inflammatory Bowel Disease (IBD) or gastroparesis.
  • Have chronic malnutrition condition.
  • History of major surgery which potentially limits participation or completion of the study.
  • History of previous intestinal surgery known to affect food intake or digestive function, including bariatric surgery.
  • Use of antibiotics, antifungal medications, probiotics or prebiotics 90 days before the start of the study.
  • Are taking the following medications: , amiodarone and/or perhexiline.
  • Are currently following or anticipated to commence a specialised commercially available weight loss diet and/or program or concomitant use of any weight loss medication or herbal weight loss products.
  • History of side effects towards probiotics or prebiotics.
  • History or current psychiatric illness.
  • History or current neurological condition (e.g. epilepsy).
  • Participants with other liver abnormalities.
  • Evidence of monogenic metabolism diseases such as Lysosomal acid lipase deficiency (LALD), Wilson disease, Hypobetalipoproteinemia, or inborn errors of metabolism.
  • Have had a weight change exceeding 3 kg within 3 months.
  • Uncontrolled diabetes, active , or chronic infections.
  • Having symptoms of active infection.
  • Excessive alcohol intake defined as self-reported intakes greater than 21 units per week in men, and 14 units per week in women.
  • Participants who are pregnant, breast feeding or actively planning pregnancy will be excluded from the study.
  • Participation in any other trial in the last 3 months.

Exclusion criteria for healthy volunteers MRI scans and patients optional MRI scans:

  • for MRI scanning: having pacemakers, defibrillators, neurostimulators, prohibited medical implants, and foreign bodies (e.g. bullets, shrapnel, metal slivers), history of metallic foreign body in eye(s) and penetrating eye injury that could present a risk during an MRI scan.
  • Difficulty breathing or inability to lie flat, as well as conditions that could worsen under stress (such as anxiety or panic disorders, claustrophobia, uncontrolled hypertension, or seizure disorders) severe enough to prevent undergoing an MRI.
Terms in these criteria, in plain language(6)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

HbA1c

A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

05

Study design

Phase
Not applicable
Primary purpose
Basic science
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
45 participants (estimated)

Study arms

  • Active comparator
    Pectin

    15g/day of pectin with 10g/day of cocoa powder added as flavour will be provided to participants for 6 weeks.

    Dietary Supplement: Pectin

  • Placebo comparator
    Cocoa Powder

    10g/day of cocoa powder will be provided to participants for 6 weeks.

    Other: Cocoa Powder

  • Other
    Magnetic resonance imaging (MRI) Validation

    To validate MRI scans as a tool to assess intestinal wall thickness to indicate gut permeability on MASLD patients, the investigators will scan 15 healthy volunteers twice, at baseline and after 6 weeks, and then compare their results with MASLD participant results at baseline and after 6 weeks.

    Diagnostic Test: Magnetic Resonance Imaging with Contrast

Interventions

  • Dietary supplementPectinsStudies of PectinsPectins pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.

    15g of pectin with 10g of cocoa powder added as flavour were randomly allocated to eligible participants.

  • OtherCocoa Powder

    10g of cocoa powder served as the control/ placebo to compare the effects observed with pectin.

  • Diagnostic testMagnetic Resonance Imaging with Contrast

    To validate MRI scans as a tool to assess intestinal wall thickness to indicate gut permeability on MASLD patients, the investigators will scan 15 healthy volunteers twice, at baseline and after 6 weeks, and then compare their results with MASLD participant results at baseline and after 6 weeks.

    Also known as: MRI

06

What researchers measure

Primary outcomes

  1. Quantification of blood markers contributing to systemic inflammation pathway (TNFα (pg/mL), IL-6 (pg/mL), IL-10 (pg/mL), IFNᵞ (pg/mL), C-Reactive Protein (pg/mL), Zonulin (Haptoglobulin)(pg/m), IL-1β(pg/mL)).

    Change in circulating markers of inflammation measured by ELISAs in serum samples collected pre and post the 6-weeks intervention period.

    Time frame: 6 weeks

Secondary outcomes

  1. Change in BMI (kg/m²)

    Changes in BMI pre and post the 6-weeks intervention period.

    Time frame: 6 weeks

  2. Assessment of changes in general metabolic indicators, such as fasting blood glucose and other blood-based markers relevant to MASLD (e.g., CK18-M30, CK18-M65, PROC3, Enhanced Liver Fibrosis (ELF), NIS2+™, YKL-40, microRNA miR-34a-5p)

    Changes in general metabolic indicators, such as fasting blood glucose and other blood-based markers relevant to MASLD (e.g., CK18-M30, CK18-M65, PROC3, Enhanced Liver Fibrosis (ELF), NIS2+™, YKL-40, microRNA miR-34a-5p) pre and post the 6-weeks intervention period.

    Time frame: 6 weeks

  3. Assessment of changes in liver-associated enzymes such as Alanine Aminotransferase (ALT), Aspartate Aminotransferase (AST), gamma-glutamyl transferase (GGT), Alkaline Phosphatase (ALP)), bilirubin levels, lipid profiles, and platelet counts.

    Changes in liver-associated enzymes such as Alanine Aminotransferase (ALT), Aspartate Aminotransferase (AST), gamma-glutamyl transferase (GGT), Alkaline Phosphatase (ALP)), bilirubin levels, lipid profiles, and platelet counts pre and post the 6-weeks intervention period.

    Time frame: 6 weeks

  4. Change in Liver Stiffness via Transient Elastography

    CAP and liver stiffness (in kPa) measured using transient elastography.

    Time frame: 6 weeks

  5. Change in Liver Fat Fraction Assessed by Dixon MRI Sequence.

    Fat fraction (%) in liver and abdominal organs assessed using Dixon MRI before and after the 6-week intervention.

    Time frame: 6 weeks

  6. Change in Intestinal Permeability Measured by T2* MRI.

    T2\* values in gut wall tissue will be compared before and after the intervention as a proxy for gut permeability.

    Time frame: 6 weeks

  7. Investigation the presence of gene variants such as MUC2, encoding Mucin protein, that are associated with gut permeability.

    Genetic variants such as MUC2 will be determined where consent for genetic analysis is given.

    Time frame: 6 weeks

  8. Change in Systolic Blood Pressure (mmHg)

    Change in Systolic Blood Pressure (mmHg) before and after the 6-week intervention.

    Time frame: 6 weeks

  9. Change in Diastolic Blood Pressure (mmHg)

    Change in Diastolic Blood Pressure (mmHg) before and after the 6-week intervention.

    Time frame: 6 weeks

  10. Change in Heart Rate (beats/minute)

    Change in Heart Rate (beats/minute) before and after the 6-week intervention.

    Time frame: 6 weeks

  11. Change in Waist-to-Hip Ratio

    Change in Waist-to-Hip Ratio before and after the 6-week intervention.

    Time frame: 6 weeks

07

Study locations

3 of 3 sites recruiting
  • University of Nottingham
    Nottingham, United Kingdom NG7 2UH, United Kingdom
    Recruiting
    • Noor K Al-Tameemi, PhD student candidate · Contactnoorkifahabdulhussein.al-tameemi@nottingham.ac.uk · 0044 01158231149
    • Guruprasad P Aithal, Professor · Contactguru.aithal@nuh.nhs.uk · 0044 01158231149
    • Noor K Al-Tameemi, PhD student candidate · Sub investigator
    • Guruprasad P Aithal, Professor · Principal investigator
    • Jane Grove, Associate Professor · Sub investigator
    • Ana Valdes, Professor · Sub investigator
  • Sir Peter Mansfield Imaging Centre, University of Nottingham
    Nottingham, NG7 2QX, United Kingdom
    Recruiting
    • Noor K Al-Tameemi, PhD student candidate · Contactnoorkifahabdulhussein.al-tameemi@nottingham.ac.uk · 0044 01158231149
    • Guruprasad P Aithal, Professor · Contactguru.aithal@nottingham.ac.uk · 0044 01158231149
    • Noor K Al-Tameemi, PhD student candidate · Sub investigator
    • Jane Grove, Associate Professor · Sub investigator
    • Guruprasad P Aithal, Professor · Principal investigator
    • Caroline Hoad · Sub investigator
    • Penny Gowland, Professor · Sub investigator
    • Susan Francis, Professor · Sub investigator
  • Nottingham Clinical Research Facility at Nottingham University Hospitals NHS Trust
    Nottingham, NG7 2UH, United Kingdom
    Recruiting
    • Noor K Al-Tameemi, PhD student candidate · Contactnoorkifahabdulhussein.al-tameemi@nottingham.ac.uk · 0044 01158231149
    • Guruprasad P Aithal, Professor · Contactguru.aithal@nottingham.ac.uk · 0044 01158231149
    • Noor K Al-Tameemi, PhD student candidate · Sub investigator
    • Jane P Grove, Associate Professor · Sub investigator
    • Guruprasad P Aithal, Professor · Principal investigator
08

References and documents

Publications

  • Al-Tameemi NK, Grove JI, Hoad CL, Wai JWS, Olaru A, Mandal S, Rollins KE, Bradley CR, Francis ST, Gowland PA, Valdes AM, Aithal GP. The impact of pectin supplementation on systemic inflammation pathways, gut microbiome, and metabolic health in patients with Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD): A study protocol for a randomised controlled trial. PLoS One. 2026 Jul 13;21(7):e0352397. doi: 10.1371/journal.pone.0352397. eCollection 2026. PubMed 42441559 ↗

Individual participant data

Plan to share: Undecided

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Jun 2025 (actual). Primary completion is estimated for Mar 2027, 21 months after the start.

Of 356 non-industry interventional studies with no phase under Non-alcoholic Fatty Liver Disease, half reached primary completion within 26 months of starting (the median), counting those still running; a quarter within 12 and three quarters within 51. This study's planned 21 months is below that.

Counting every sponsor, half of 384 studies reached it within 25 months; a quarter within 12 and three quarters within 48.

How these figures are worked out, and which studies are left out of them.

Registered
Jul 8, 2025
First posted
Jul 30, 2025
StartActual
Jun 10, 2025
Primary completionEst.
Mar 31, 2027
CompletionEst.
Mar 31, 2027
Last update
Jul 29, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 29, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07093346
Responsible party
Sponsor
First posted
Jul 30, 2025
Start date
Jun 10, 2025
Primary completion
Mar 31, 2027 (estimated)
Completion
Mar 31, 2027 (estimated)
Last update
Jul 29, 2026

Study contacts

Noor K Al-Tameemi, PhD student candidate
Contact
noorkifahabdulhussein.al-tameemi@nottingham.ac.uk
0044 01158231149
Guruprasad P Aithal, Professor
Contact
guru.aithal@nottingham.ac.uk
0044 01158231149
Noor K Al-Tameemi, PhD student candidate
study director · Nottingham Digestive Diseases Centre & NIHR Nottingham Biomedical Research Centre, Nottingham, University Hospitals NHS Trust and the University of Nottingham, Queens Medical Centre Nottingham, NG7 2UH
Guruprasad P Aithal, Professor
principal investigator · Nottingham Digestive Diseases Centre & NIHR Nottingham Biomedical Research Centre, Nottingham, University Hospitals NHS Trust and the University of Nottingham, Queens Medical Centre Nottingham, NG7 2UH
Jane Grove, Associate Professor
study director · Nottingham Digestive Diseases Centre & NIHR Nottingham Biomedical Research Centre, Nottingham, University Hospitals NHS Trust and the University of Nottingham, Queens Medical Centre Nottingham, NG7 2UH

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Pectins

Start the discussion